Seroquel XR in Schizophrenia Relapse Prevention

AstraZeneca

Status: Completed

Conditions: Schizophrenia Relapse Prevention

Study type: Observational

Funder types: Industry

Identifiers

NCT00990626

NIS-NHU-SER-2009/1

Details and patient eligibility

About

The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improve the relapse prevention in schizophrenic outpatients

Enrollment: 1,600 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Schizophrenic outpatients on at least 600 mg Seroquel XR treatment for at least 1 month

Exclusion criteria

• Severe cerebro- and cardiovascular disease, severe hepatic impairment, gravidity

Trial design

1,600 participants in 1 patient group

1

Description:

Schizophrenic outpatients